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Abstract
Aloin is a physiologically active anthraquinone present in aloe. There are two isomers of aloin, aloin A and aloin B, occurring as a mixture 
of diastereomers. The objective of this study was to determine the bioavailability and tissue distribution of aloin. Rats were gavaged with 11.8g/kg
aloin, and the levels of aloin and its conjugates were measured in plasma, tissues, and urine. Plasma aloin level showed a peak at 1hr after the
administration and the concentration was 59.07±10.5 ng/ml. The 24 h cumulated urinary aloin was 0.03% of the initial dose. These results suggest
that aloin is absorbed and reaches a peak plasma level within 1-1.5 h after the administration and a significant portion is possibly metabolized
or is excreted in feces. These results can apply to the determination of the adequate intake level of aloe and aloe products to achieve the desired
biological effect, and to interprete in vitro study results. 
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Fig. 1. Chemical structures of aloin A and aloin B
Introduction4)
Aloe is widely used in food products, pharmaceuticals, and 
cosmetics due to its aromatic and therapeutic properties (Davis, 
1994; Korkina, 2003). Aloe products have been used to alleviate 
inflammation and accelerate wound healing and its products 
ranked first in health food sales of 2005 (Park et al., 2005). 
Biologically active substrates in aloe include anthraquinone, 
anthrone derivatives, polysaccharides and chromones (Tom, 
2004). Although aloe has been studied for its efficacy, the 
pharmacokinetic properties of its ingredients are largely un-
known. Aloin is the major anthraquinone of aloe exudates and 
gels (Groon & Reynols, 1986) and it is characterized as the 
C-glycoside of aloe-emodin (Fig. 1.) (Reynold, 1985). Biological 
effects of aloin have been examined in a limited number of 
studies. Aloin increased the alcohol oxidation rate in rats (Chung 
et al., 1996), inhibited AOM-induced DNA adduct formation in 
rats (Shimpo et al., 2003), and had cytotoxicity against human 
breast cancer cell lines (Esmat et al., 2006). Even with these 
biological functions, the aloin content in aloe products is strictly 
regulated due to its possible adverse effects including laxative 
property (Koch, 1996) and cytotoxicity (Avila et al., 1997). Since 
these biological efficacies of aloin depend on its bioavailability, 
it is important to understand the absorption and tissue distribution 
of aloin as a basis for analyzing its benefits and risks. To produce 
data useful in interpreting many studies regarding in vitro 
efficacy and toxicity, we investigated the fate of oral aloin intake 
in rats.
Materials and Methods
Chemicals and reagents 
Aloin, β-D-glucuronidase and sulfatase were purchased from 
Sigma-Aldrich Co. (St. Louis, MO, USA). All other chemicals 
and solvents (HPLC grade) were obtained from Waters Korea 
Co. (Seoul, KOREA). The standard stock solution of aloin was 
made in 70% methanol and stored at -80℃ until use.
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Fig. 2. Plasma concentration-time curve of aloin in rats after gavage 
administration of aloin at 11.8 g/kg rat body weight. Results are expressed as 
mean ± SD  on  a  sample  size  of  four  rats/group. 
Table 1. Plasma concentration of aloin oral administration (11.8 g/kg) in rats
(n=4)
a)
Aloin A (ng/ml) Aloin B (ng/ml)
Aloin A Aloin A-glu/sul







0.5 h 10.34 ± 0.32
a 14.02 ± 3.18
b 8.54 ± 0.69
a 13.85 ± 2.58
a
1 h 11.82 ± 0.52
a 15.00 ± 4.55
a 9.39 ± 0.27
a 14.07 ± 1.07
a
1.5 h  8.58 ± 1.27
b  7.77 ± 1.19
c 7.10 ± 0.74
b  5.56 ± 2.59
b
3 h  7.90 ± 0.53
b  4.71 ± 1.58
cd 7.14 ± 0.77
b  2.89 ± 0.32
c
5 h  4.93 ± 0.15
c  5.92 ± 2.60
cd 4.95 ± 0.97
c  1.37 ± 0.35
cd
8 h   4.39 ± 0.46
cd  2.75 ± 0.23
cd 2.17 ± 0.20
d  1.13 ± 0.29
cd
12 h   3.45 ± 0.06
de  1.58 ± 0.26
d 1.92 ± 0.11
de  1.14 ± 0.29
cd
24 h  3.05 ± 0.21
ef  1.38 ± 0.12
d 1.44 ± 0.23
ef  0.98 ± 0.24
cd
48 h  2.32 ± 0.30
fg  1.86 ± 0.05
d 0.64 ± 0.02
f 0.58 ± 0.01
d
72 h 1.54 ± 1.54
g  1.23 ± 0.01
d 0.61 ± 0.02
f 0.61 ± 0.01
d
a) Values are means ± SD, n=4. Means in a row with different superscript letters 
are  significantly  different  (p＜0.05).
b) A l o i n  A  g lu c u r o n i d e / s u l f a t e  c o n j u g a t e  f o r m
c)  Aloin  B  glucuronide/sulfate  conjugate  form
Treatment of animals and blood sample collection
Male Sprague-Dawley rats were obtained at 7 weeks of age from 
Jung-Ang Lab Animal Inc. (Seoul, Korea) and maintained in 
air-conditioned quarters with 12-hr light/dark cycles. They were 
given a commercial rat food (Jung-Ang Lab Animal Inc., Seoul, 
Korea) and water ad libitum. The experiments started after the 
rats were given at least 1 week to adapt to their new diet and 
environment. A fresh dose of aloin solution was made with water 
and administered at dose of 11.8 g/kg. Blood samples were 
collected from the heart at 0.5, 1, 1.5, 3, 5, 8, 12, 24, 48, and 
72 h after the aloin was administered, and placed in heparinized 
tubes. The blood samples were centrifuged at 2,000 × g for 10 
min. The plasma was stored at -80℃  until it was used. 
Tissue and urine sample collection 
Rats were randomly divided into 11 groups (four rats per 
group), and given aloin gavage at a dose of 11.8 g/kg. To collect 
urine, rats were kept in metabolic cages. The animals were 
sacrificed at 0, 0.5, 1, 1.5, 3, 5, 8, 12, 24, 48, and 72 h after 
the aloin administration. Liver, kidney, and intestine (20 cm from 
the stomach) were removed and homogenized with 1 ml of 0.4 
M sodium phosphate buffer containing 6 mg of ascorbic acid 
and 0.5 mg of Na2EDTA (final pH of 6.5). Tissue homogenates 
were centrifuged at 16,000 × g for 5min, and 200 µl of the 
supernatant was used to analyze aloin. The results were expressed 
on the basis of the weight of wet tissues (µg/g). Urine samples 
were collected before and at 0-24, 24-48, and 48-72 h after the 
aloin administration. The urine samples were stored at -80℃ until 
they were used.
Quantitation of aloin
The levels of aloin in rat plasma, tissues, and urine were 
determined by HPLC. The HPLC system consisted of a Waters 
600 Controller, Waters 600 Pump, and Waters 486 Detector 
(Waters Korea Co., Seoul, Korea). The sample was incubated 
with β-D-glucuronidase and sulfatase at 37℃ for 45 min. The 
reaction mixture was then extracted with ethyl acetate, and the 
extract was dried under LN2. The residues were reconstituted 
in 200 µL of 50% methanol. After the resultant solution was 
centrifuged at 12,000 × g for 10 min, 15 µL of aliquots were 
injected into the HPLC column. A Symmetry C18, 4.6´250 mm, 
column was used with a mobile phase of methanol-water (50:50) 
at a flow rate of 0.9 ml/min and detection at 220 nm. 
Statistical analysis
Values were expressed as means ± SD. Duncan’s multiple 
range test was performed to determine significant differences 
among the groups. A p<0.05 was considered as statistically 
significant.
Results
Plasma concentration of aloin
The plasma concentration-time curves of aloin and its glucu-
ronides after the administration of aloin are shown in Fig. 2. 
The plasma samples obtained from rats were analyzed for the 
presence of both free and conjugated aloin. In rats receiving aloin 
(11.8 g/kg), plasma levels were detectable as early as 0.5 h, and 
peaked at 1 h followed by a subsequent decline. The plasma 
concentration at peak level was 59.07 ± 10.5 ng/ml. The plasma 
concentrations of both free and conjugates at different time points 
are given in Table 1. Fifty percent of total aloin in plasma was 
in the form of aloin glucuronide. 
Tissue concentration of aloin
The tissue levels of aloin over time are shown in Fig. 3. The 
peak levels of aloin in liver and intestine were 77.15 ± 15.92 ng/g 
and 102.37 ± 14.12 ng/g, respectively, at 0.5 h (Table 2). The 
levels declined rapidly within 90 min. Aloin concentration in the 
kidney was maximized as 12.46 ± 0.81 ng/g at 5 h (Table 2).Mi-Young Park et al. 19
Fig. 3. Tissue concentration of aloins (aloin A, aloin B, conjugates) in rats after 
gavage administration of aloin at 11.8 g/kg rat body weight. Results  are 
expressed  as  mean ± SD  on  a  sample  size  of  four  rats/group.
Table 2. Tissue concentration of aloins (aloin A, aloin B, conjugates) in rats 
after aloin (11.8 g/kg) gavage
a)
Aloin A (ng/g) Aloin B (ng/g)
Aloin A Aloin A-glu/sul
b) Aloin B Aloin B-glu/sul
c)
Intestine




0.5 h 51.26 ± 14.77
a 2.32 ± 0.85
a 48.33 ± 14.98
a 2.07 ± 1.16
a
1.5 h 18.92 ± 9.66
b 2.05 ± 1.12
a 10.63 ± 2.13
b 0.75 ± 0.12
a
5.0 h 8.03 ± 1.95
b 2.07 ± 1.40
a 6.92 ± 1.00








0.5 h 26.7 ± 5.84
a 18.39 ± 16.91
ab  31.3 ± 13.11
a 2.38 ± 1.92
a
1.5 h 8.26 ± 1.87
b 2.09 ± 1.21
b 6.23 ± 1.05
b 0.80 ± 0.17
a
5.0 h 5.17 ± 0.73
b 1.49 ± 0.31
b 3.39 ± 0.37








0.5 h 2.75 ± 0.67
c 1.34 ± 0.12
a 1.44 ± 0.57
c 0.63 ± 0.12
a
1.5 h 3.89 ± 0.37
b 1.22 ± 0.11
a 2.98 ± 0.30
b 0.54 ± 0.15
a
5.0 h 5.84 ± 0.31
a 1.30 ± 0.19
a 4.52 ± 0.10
a 0.80 ± 0.02
a
a) Values are means ± SD, n=4. Means in a row with different superscript letters 
are  significantly  different  (p＜0.05).
b) A l o i n  A  g lu c u r o n i d e / s u l f a t e  c o n j u g a t e  f o r m
c)  Aloin  B  glucuronide/sulfate  conjugate  form
Fig. 4. Urinary excretion of aloins (aloin A, aloin B, conjugates) in rats after 
gavage administration of aloin at 11.8 g/kg rat body weight. Results  are 
expressed  as  mean±SD  on  a  sample  size  of  four  rats/group.
Table 3. Urinary extraction of aloins (aloin A, aloin B, conjugates) in rats after
aloin (11.8g/kg) gavage for 3d 
a)
Aloin A (µg/d) Aloin B (µg/d)
Aloin A Aloin A-glu/sul
b) Aloin B Aloin B-glu/sul
c)




1 d 2.80 ± 1.10
a 0.90 ± 0.80
a 0.42 ± 0.21
a 0.19 ± 0.15
a
2 d 0.50 ± 0.29
b 0.30 ± 0.20
a 0.16 ± 0.10
ab 0.08 ± 0.06
a
3 d 0.30 ± 0.50
b 0.20 ± 0.15
a 0.07 ± 0.06
b 0.05 ± 0.03
a
a) Values are means ± SD, n=4. Means in a row with different superscript letters 
are  significantly  different  (p＜0.05).
b) A l o i n  A  g lu c u r o n i d e / s u l f a t e  c o n j u g a t e  f o r m
c)  Aloin  B  glucuronide/sulfate  conjugate  form
Urinary concentration of aloin
Urinary aloin and its conjugates were excreted within 72 h 
of the administration (Table 3). Most of the urinary aloin was 
excreted within 24 h. The cumulative amount of aloin excreted 
in the urine during the first 24 h was 0.03% of the administrated 
dose. The cumulative excretion of aloin A and aloin B within 
24 h amounted to 2.8 ± 1.1 µg/day and 0.42 ± 0.21 µg/day, 
respectively. These values correspond to 64.97 and 9.7% of the 
administered doses, respectively.
Discussion
The aim of this study was to evaluate the absorption and 
urinary excretion of aloin to gain a better understanding of its 
bioavailability and tissue distribution as a basis to interpret in 
vitro studies, and to determine effective level of intake. To 
determine its in vivo bioavailability, we used 11.8 g/kg which 
was LOAEL of aloin (Zhou et al., 2003). 
In this study, the level of aloin and their conjugates in plasma 
peaked at 1 h suggesting a rapid absorption of aloin in the 
gastrointestinal tract. At the peak plasma aloin level, conjugates 
of both aloin A and aloin B levels were higher compared to 
the levels of free aloin A and aloin B. The AUC0-24hr of aloin 
was determined as 270.81 ± 59.1 ng․h/ml and the half lives of 
aloin was 1.47 ± 0.24 hr. To maintain a high concentration in 
plasma, it requires a repeated ingestion of aloin every 1.5 h. The 
published studies in cell culture system used 50-2500 µM of aloin 
(Esmat et al., 2005; Wamer et al., 2003). However, the mean 
peak plasma level was 0.026 µM after the consumption of 11.8 
g/kg. Thus this value could serve as a reference for designing 
and interpreting in vitro experiments for elucidating the mecha-
nisms of action of aloin. Recently, several studies have shown 
that oral intake leads to anti-cancer (Shimpo et al., 2003) and 
anti-diabetic effects (Bolkent et al., 2004; Can et al., 2004). 
These are evidences to support either that the low aloin concen-
trations are adequate to induce biochemical changes, or that 
localized tissue aloin is metabolized to more active form(s).
Many in vitro studies have used high concentrations of aloin 
to test their efficacy presuming that most of aloin consumed 
would enter the circulation. However, a limited number of studies 
have been conducted for intestinal metabolism of anthraquinones. 
Our preliminary in vitro experiment using Caco-2 cell model 
showed that the absorption rate of aloin was about 6.6% which 
was similar to the absorption rate of other polyphenols (unpu-
blished data). Due to the β-glycosidic linkage between the sugar 20 Absorption and tissue distribution of aloin in rats
and anthranoid structure, the glycoside form is protected against 
both hydrolysis by acid in the stomach and α-glucosidase activity 
in the small intestine (Wolffram et al., 2002). Results showed 
that native aloin as well as glucuronate or sulfate conjugates was 
identified in the jejunum indicating that aloin is absorbed in the 
small intestine and subjected to the action of various conjugation 
enzymes present in the small intestine. There are very few data 
on intestinal metabolism of anthraquinone. Although the absor-
ption mechanisms of anthraquinones as glycosides are not clear, 
glycosidic polyphenols are transported into enterocyte by inte-
stinal glucose transporters (GLUTs and SGLT) (Olthof et al., 
2000) and can be hydrolyzed by a cytosolic β-glucosidase (Day 
et al., 1998). Another pathway involves the lactase phloridzine 
hydrolase (LPH), on the outside of the brush border membrane 
of the small intestine that catalyzes extracellular hydrolysis of 
glucosides (Day et al., 2000). Both enzymes are probably in-
volved although their relative contribution for various glucosides 
is not clear. Moreover, part of them are transported by efflux 
into the intestinal lumen by multidrug resistance-associated 
protein 2 (MRP2) (Walle et al., 1999). Both phase I and phase 
II detoxification enzymes are expressed in the enterocytes. Gly-
cosidic polyphenols are converted to polar β-glucuronides by 
phase II UDP-glucuronyltransferase (UGTs) (Jäger et al., 1998). 
These indicated that the absorption and metabolism of glycosidic 
polyphenols is complex, and requires further investigation. 
The liver receives aloin from the mesenteric vein. We analyzed 
the aloin levels in the liver at several sampling times (0.5, 1.5, 
and 5 h after aloin gavage). After a short period of time, aloin 
was detectable in the liver (Table 2). The presence of a high 
proportion of glucuronidated aloins in rat liver possibly suggests 
that a significant extent of metabolism occurs in the liver. Since 
we measured total aloin and not aloe-emodin, aloin may also 
be converted to aloe-emodin by liver enzymes. Aloe-emodin can 
be biotransformed to 2-hydroxyemodin in the liver by cyto-
chrome P450 1A2 (Mueller et al., 1998). In pharmacokinetic- 
metabolic studies with aloe-emodin, 15% of the dose was 
excreted in urine and the rest in feces (Maity et al., 2001). In 
this study, glucuronic acid or sulfate conjugated forms of aloin 
were also detected in the kidney, although aloin presented as 
an unconjugated form in the majority of tissues (intestine, liver 
and kidney). These results indicate that aloin undergoes decon-
jugation process when it enters the tissue. In liver cells, β
-glucuronidase is responsible for the metabolism of polyphenol 
glucuronides (O'Leary et al., 2003). 
Native aloin as well as its glucuronidated or sulfated meta-
bolites was present in urine and their excretion rate was relatively 
low as compared to the amount ingested. In this study, urinary 
recovery of aloin was 0.03% of the oral intake. This finding 
is in agreement with the results of several other investigations 
which found that excretion rate of polyphenols in urine were 
between 0.005-0.1% of the intake (Bub et al., 2001; Chen et 
al., 1997; Matsumoto et al., 2001). Excretion percentages of aloin 
A and aloin B in urine were 64.7 and 9.7% of total aloin, 
respectively, indicating that aloin B would be more effective form 
of aloin than aloin A in rats. In a study using tea cathechins, 
β-elimination half-lives of epigallocatechin-gallate (EGCG) was 
greatest followed by epigallocatechin (EGC) and then epicatechin 
(EC), and EGCG is known as a strong antioxidant, anti-inflam-
matory and anti-cancer agent in green tea (Kim et al., 2006; 
Landis-Piwowar  et al., 2007; Rice-Evans et al., 1995). These 
studies indicate that larger proportion of compounds circulating 
is possibly associated with its biological activity in vivo. In other 
bioavailability studies of polyphenols, they often reached the 
peak plasma level at 1-2 h after oral administration and then 
were rapidly decreased (Chen et al., 1997; Chow et al., 2001). 
In agreement with these results, aloin is also rapidly taken up 
and then excreted. Consequently, the fast excretion of aloin is 
facilitated by the conjugation of the aglycon to sulfate and 
glucuronide groups like other polyphenols. These pharmaco-
kinetic parameters are useful for selecting the dose and dose 
frequency of aloe consumption for human studies.
This study confirmed that aloin was absorbed in its unchanged 
glycated forms in vivo. Further work is required to characterize 
the aloin metabolites and asses their potential biological activity 
at practical plasma concentrations. 
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